更正：在需要口服抗凝治疗和经皮冠状动脉介入治疗的患者中，低剂量普拉格雷与氯吡格雷作为三联抗栓治疗一部分的短期临床结局比较。
Correction: Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention.
作者信息
Kitahara Hideki, Tateishi Kazuya, Shiko Yuki, Inaba Yusuke, Kobayashi Yoshio, Inoue Takahiro
出版信息
PLoS One. 2023 Oct 31;18(10):e0293937. doi: 10.1371/journal.pone.0293937. eCollection 2023.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0272140.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0272140。]
相似文献
1
Correction: Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention.
PLoS One. 2023 Oct 31;18(10):e0293937. doi: 10.1371/journal.pone.0293937. eCollection 2023.
2
Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention.
PLoS One. 2022 Jul 28;17(7):e0272140. doi: 10.1371/journal.pone.0272140. eCollection 2022.
3
Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - From the TWMU-AF PCI Registry.
Circ J. 2019 Apr 25;83(5):1000-1005. doi: 10.1253/circj.CJ-18-1113. Epub 2019 Mar 27.
4
Dual antithrombotic therapy with oral anticoagulant and P2Y12 inhibitors in patients with atrial fibrillation after percutaneous coronary intervention.
J Cardiol. 2023 Sep;82(3):207-214. doi: 10.1016/j.jjcc.2023.06.002. Epub 2023 Jun 17.
5
Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
J Cardiovasc Pharmacol Ther. 2017 Nov;22(6):546-551. doi: 10.1177/1074248417698042. Epub 2017 Mar 9.
6
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
JACC Cardiovasc Interv. 2015 Dec 21;8(14):1880-9. doi: 10.1016/j.jcin.2015.08.018.
7
Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):625-629. doi: 10.1177/10742484211031436. Epub 2021 Jul 8.
8
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Circulation. 2007 Dec 18;116(25):2923-32. doi: 10.1161/CIRCULATIONAHA.107.740324. Epub 2007 Dec 3.
9
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Am J Med. 2016 Jun;129(6):592-599.e1. doi: 10.1016/j.amjmed.2015.12.026. Epub 2016 Jan 18.
10
Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: Traditional and Bayesian meta-analysis of clinical trials.
Int J Cardiol. 2016 Feb 15;205:89-96. doi: 10.1016/j.ijcard.2015.12.005. Epub 2015 Dec 17.
本文引用的文献
1
Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention.
PLoS One. 2022 Jul 28;17(7):e0272140. doi: 10.1371/journal.pone.0272140. eCollection 2022.
Zotero 插件